TNF receptor 2 pathway: drug target for autoimmune diseases.
Although drug development has advanced for autoimmune diseases, many current therapies are hampered by adverse effects and the frequent destruction or inactivation of healthy cells in addition to pathological cells. Targeted autoimmune therapies capable of eradicating the rare autoreactive immune cells that are responsible for the attack on the body's own cells are yet to be identified. This Review presents a new emerging approach aimed at selectively destroying autoreactive immune cells by specific activation of tumour necrosis factor receptor 2 (TNFR2), which is found on autoreactive and normal T lymphocytes, with the potential of avoiding or reducing the toxicity observed with existing therapies.
Faustman
Denise
D
Immunobiology Laboratory, Room 3602, Building 149, Massachusetts General Hospital and Harvard Medical School, 13th Street, Charlestown, Massachusetts 02129, USA. faustman@helix.mgh.harvard.edu
Davis
Miriam
M
D001327:Autoimmune Diseases / Q000188:drug therapy*; D017252:CD3 Complex / Q000276:immunology; D006801:Humans; D016328:NF-kappa B / Q000502:physiology; D020239:Receptor Cross-Talk; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000502:physiology; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000819:agonists* / Q000502:physiology; D015398:Signal Transduction
D017252:CD3 Complex; D016328:NF-kappa B; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II